INBX 8-K: SEC filing

Inhibrx Biosciences

Filed with the SEC on · accession 0002007919-26-000063

INBX filed a 8-K (current report) with the SEC on Nov 17, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Inhibrx Biosciences announced updated clinical data from a Phase 1/2 expansion study of ozekibart (INBRX-109) in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma, to be presented at the Connective Tissue Oncology Society 2026 Annual Meeting.

Key details

RegistrantInhibrx Biosciences, Inc.
Chief financial officerKelly Deck

✦ Ask GOAX AI about this filing — what it means for INBX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for INBX?

Click here

Frequently asked questions

What did INBX file with the SEC on Nov 17, 2026?

INBX filed a 8-K (SEC filing). Inhibrx Biosciences announced updated clinical data from a Phase 1/2 expansion study of ozekibart (INBRX-109) in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma, to be presented at the Connective Tissue Oncology Society 2026 Annual Meeting.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other INBX SEC filings

Get alerts when INBX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days